CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in ...

In all, their investment portfolio pulled in an estimated 54% return in 2024, more than double the S&P 500’s 25% gain — and ...

The UK's FTSE 100 saw its five-week winning streak halted, influenced by global tensions between Israel and Iran, and ...

AstraZeneca PLC closed 22.38% below its 52-week high of £133.88, which the company achieved on September 3rd.

According to Benzinga Pro, AstraZeneca's peer group average for short interest as a percentage of float is 3.86%, which means ...

AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. | AstraZeneca has ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Metabolism and obesity are the focus of a major research initiative by the University of Gothenburg and AstraZeneca, with the ...

Astrazeneca AB has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to an estrogen receptor α (ER-α)-targeting moiety ...